 Connection
Stanley Szefler to Adrenergic beta-Agonists
This is a "connection" page, showing publications Stanley Szefler has written about Adrenergic beta-Agonists.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.477 |
|
|
|
-
Hoch HE, Szefler SJ. Intermittent steroid inhalation for the treatment of childhood asthma. Expert Rev Clin Immunol. 2016; 12(2):183-94.
Score: 0.487
-
Anderson WC, Szefler SJ. New and future strategies to improve asthma control in children. J Allergy Clin Immunol. 2015 Oct; 136(4):848-59.
Score: 0.480
-
Rabinovitch N, Mauger DT, Reisdorph N, Covar R, Malka J, Lemanske RF, Morgan WJ, Guilbert TW, Zeiger RS, Bacharier LB, Szefler SJ. Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma. J Allergy Clin Immunol. 2014 Feb; 133(2):350-6.
Score: 0.421
-
Szefler SJ, Chinchilli VM, Israel E, Denlinger LC, Lemanske RF, Calhoun W, Peters SP. Key observations from the NHLBI Asthma Clinical Research Network. Thorax. 2012 May; 67(5):450-5.
Score: 0.382
-
Szefler SJ, Busse WW. Adding LABAs to inhaled glucocorticoids for asthma. N Engl J Med. 2011 09 29; 365(13):1260-1; author reply 1261.
Score: 0.366
-
Bisgaard H, Szefler S. Long-acting beta2 agonists and paediatric asthma. Lancet. 2006 Jan 28; 367(9507):286-8.
Score: 0.247
-
Anderson WC, Szefler SJ. Controlling the Risk Domain in Pediatric Asthma through Personalized Care. Semin Respir Crit Care Med. 2018 Feb; 39(1):36-44.
Score: 0.142
-
Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, Lazarus SC, Lemanske RF, Martin RJ, Peters SP, Sorkness C, Szefler SJ. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med. 1996 Sep 19; 335(12):841-7.
Score: 0.129
-
Szefler SJ. Advances in pediatric asthma in 2014: Moving toward a population health perspective. J Allergy Clin Immunol. 2015 Mar; 135(3):644-52.
Score: 0.115
-
Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L, Fahy JV, Jarjour N, Kazani S, Kim S, Kraft M, Lazarus SC, Lemanske RF, Markezich A, Martin RJ, Permaul P, Peters SP, Ramsdell J, Sorkness CA, Sutherland ER, Szefler SJ, Walter MJ, Wasserman SI, Israel E. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet. 2009 Nov 21; 374(9703):1754-64.
Score: 0.081
-
Sharma S, Litonjua AA, Tantisira KG, Fuhlbrigge AL, Szefler SJ, Strunk RC, Zeiger RS, Murphy AJ, Weiss ST. Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program. J Allergy Clin Immunol. 2008 Nov; 122(5):921-928.e4.
Score: 0.075
-
Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, DiMango E, Fahy JV, Kraft M, Leone F, Lazarus SC, Lemanske RF, Martin RJ, Pesola GR, Peters SP, Sorkness CA, Szefler SJ, Israel E. Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med. 2007 Feb 01; 175(3):228-34.
Score: 0.065
-
Wechsler ME, Lehman E, Lazarus SC, Lemanske RF, Boushey HA, Deykin A, Fahy JV, Sorkness CA, Chinchilli VM, Craig TJ, DiMango E, Kraft M, Leone F, Martin RJ, Peters SP, Szefler SJ, Liu W, Israel E. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006 Mar 01; 173(5):519-26.
Score: 0.061
-
Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF, Liggett SB, Martin RJ, Mitra N, Peters SP, Silverman E, Sorkness CA, Szefler SJ, Wechsler ME, Weiss ST, Drazen JM. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004 Oct 23-29; 364(9444):1505-12.
Score: 0.056
-
Szefler SJ. Current concepts in asthma treatment in children. Curr Opin Pediatr. 2004 Jun; 16(3):299-304.
Score: 0.055
-
Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Sorkness CA, Kraft M, Fish JE, Peters SP, Craig T, Drazen JM, Ford JG, Israel E, Martin RJ, Mauger EA, Nachman SA, Spahn JD, Szefler SJ. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001 May 23-30; 285(20):2583-93.
Score: 0.045
-
Lemanske RF, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, Drazen JM, Chinchilli VM, Craig T, Fish JE, Ford JG, Israel E, Kraft M, Martin RJ, Nachman SA, Peters SP, Spahn JD, Szefler SJ. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA. 2001 May 23-30; 285(20):2594-603.
Score: 0.045
-
Leone FT, Mauger EA, Peters SP, Chinchilli VM, Fish JE, Boushey HA, Cherniack RM, Drazen JM, Fahy JV, Ford J, Israel E, Lazarus SC, Lemanske RF, Martin RJ, McGeady SJ, Sorkness C, Szefler SJ. The utility of peak flow, symptom scores, and beta-agonist use as outcome measures in asthma clinical research. Chest. 2001 Apr; 119(4):1027-33.
Score: 0.044
-
Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunselman S, Lazarus SC, Lemanske RF, Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, Szefler SJ, Weiss ST, Yandava CN. Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol. 2001 Jan-Mar; 124(1-3):183-6.
Score: 0.044
-
Szefler SJ, Bender BG, Jusko WJ, Lanier BQ, Lemanske RF, Skoner DP, Stempel DA. Evolving role of theophylline for treatment of chronic childhood asthma. J Pediatr. 1995 Aug; 127(2):176-85.
Score: 0.030
-
Szefler SJ. Anti-inflammatory drugs in the treatment of allergic disease. Med Clin North Am. 1992 Jul; 76(4):953-75.
Score: 0.024
-
Nelson HS, Szefler SJ, Martin RJ. Regular inhaled beta-adrenergic agonists in the treatment of bronchial asthma: beneficial or detrimental? Am Rev Respir Dis. 1991 Aug; 144(2):249-50.
Score: 0.023
-
Lemanske RF, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Covar RA, Guilbert TW, Larsen G, Morgan WJ, Moss MH, Spahn JD, Taussig LM. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010 Mar 18; 362(11):975-85.
Score: 0.021
-
Gruchalla RS, Sampson HA, Matsui E, David G, Gergen PJ, Calatroni A, Brown M, Liu AH, Bloomberg GR, Chmiel JF, Kumar R, Lamm C, Smartt E, Sorkness CA, Steinbach SF, Stone KD, Szefler SJ, Busse WW. Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: role of predictors in the setting of high adherence. J Allergy Clin Immunol. 2009 Aug; 124(2):213-21, 221.e1.
Score: 0.020
-
Kraft M, Martin RJ, Lazarus SC, Fahy JV, Boushey HA, Lemanske RF, Szefler SJ. Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids. Chest. 2003 Jul; 124(1):42-50.
Score: 0.013
-
Pincus DJ, Szefler SJ, Ackerson LM, Martin RJ. Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol. 1995 Jun; 95(6):1172-8.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|